Election 2014
SENSEX NIFTY
Moneycontrol.com India | Notes to Account > Finance - Investments > Notes to Account from Lifeline Drugs & Pharma - BSE: 506113, NSE: N.A
YOU ARE HERE > MONEYCONTROL > MARKETS > FINANCE - INVESTMENTS > NOTES TO ACCOUNTS - Lifeline Drugs & Pharma
Lifeline Drugs & Pharma
BSE: 506113|ISIN: INE776N01028|SECTOR: Finance - Investments
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Apr 17, 17:00
242.50
10.55 (4.55%)
VOLUME 62,823
Lifeline Drugs & Pharma is not listed on NSE
Mar 12
Notes to Accounts Year End : Mar '13
Note 1:    SEGMENT INFORMATION (AS-17)
 
 During the year company has not carried out any business activity
 except for the trading of Shares and Securities and hence Accounting
 Standard 17 SEGMENT INFORMATION is not applicable.
 
 Note 2: RELATED PARTY DISCLOSURE
 
 Related party disclosures'' as required by AS - 18'' Related Party
 Disclosures are given below:
 
 A) Directors
 
 - Alok Kumar Behra - Managing Director
 
 - Ranjit Kumar Modi - Director
 
 - Anil Kumar Sanklecha - Director A) Relationships
 
 a) Related parties where common control exists
 
 Name of the Companies where the directors can exercise the control
 
 - Prathama Trading Limited
 
 - Jubilant Fintex Private Limited
 
 - Arya Commodity & Derivatives Private Limited
 
 - Jeeva Vanijya Pvt Ltd
 
 - Eden Spring Trading Private Limited
 
 - Blue Lagoon Vanijya Private Limited1
 
 - Everything Trading Private Limited
 
 - Swapanpuri Tradelink Private Limited
 
 - Matarani Commotrade Private Limited b) Key Management Personnel
 
 Mr. Alok Kumar Behra Managing Director
 
 Mr. Ranjit Kumar Modi Director
 
 Mr. Anil Kumar Sanklecha Director
 
 C) Transactions with Related Parties-
 
 During the year under consideration no transactions with related party
 were entered into.
 
 Note 3: EARNING PER SHARE
 
 No Potential Equity Shares were outstanding as on 31.03.2013 and hence
 Basics and Diluted Earning Per Shares are Same.
 
 Note 4: Balances of Sundry Debtors'' Unsecured Loans'' Sundry Creditors
 and Loans & Advances are subject to reconciliation'' since confirmations
 have not been received from them. Necessary entries shall be passed on
 the receipt of the same if required.
 
 Note 5: In the opinion of the management'' the Current Assets'' Loans &
 Advances are approximately of the value stated'' if realized in the
 ordinary course of business. The provisions for all known liabilities
 are ascertained.
 
 Note 6: The Company has issued 18''74''000 new Equity Shares. These
 shares have been allotted at a price of Rs. 60/- each which is in
 accordance with the Preferential Issue Guidelines issued by Securities
 and Exchange Board of India.
 
 Note 7: The Company has not received the required information from
 suppliers regarding their status under the Micro'' Small and Medium
 Enterprises Development Act'' 2006. Hence disclosures'' if any'' relating
 to amounts unpaid as at the year end together with interest
 paid/payable as required under the said Act have not been made.
 
 Note 8: The Company has not provided for Gratuity and Leave Encashment
 to Employees on accrual basis'' which is not in conformity with AS - 15
 issued by ICAI. However'' in the opinion of management the amount
 involved is negligible and has no impact on Profit & Loss Account.
 
 Note 9: Previous year''s figures have been grouped/ regrouped''
 arranged/rearranged wherever necessary to make them comparable.
Source : Dion Global Solutions Limited
Quick Links for lifelinedrugspharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.